CN Patent

CN103450201B — 手性8‑（3‑氨基哌啶‑1‑基）‑黄嘌呤的制备方法

Assigned to Borui Pharmaceutical (suzhou) Ltd By Share Ltd · Expires 2017-04-12 · 9y expired

What this patent protects

本发明涉及手性8‑（3‑氨基哌啶‑1‑基）‑黄嘌呤的制备方法：3‑氨基哌啶的氨基进行保护后，与1‑[3‑腈基‑吡啶‑2‑基]‑3‑甲基‑7‑（2‑丁炔‑1‑基）‑8‑溴黄嘌呤进行反应。本发明的制备方法反应收率高，保障了8‑（3‑氨基哌啶‑1‑基）‑黄嘌呤的纯度，适合工业化生产。

USPTO Abstract

本发明涉及手性8‑（3‑氨基哌啶‑1‑基）‑黄嘌呤的制备方法：3‑氨基哌啶的氨基进行保护后，与1‑[3‑腈基‑吡啶‑2‑基]‑3‑甲基‑7‑（2‑丁炔‑1‑基）‑8‑溴黄嘌呤进行反应。本发明的制备方法反应收率高，保障了8‑（3‑氨基哌啶‑1‑基）‑黄嘌呤的纯度，适合工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN103450201B
Jurisdiction
CN
Classification
—
Expires
2017-04-12
Drug substance claim
No
Drug product claim
No
Assignee
Borui Pharmaceutical (suzhou) Ltd By Share Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.